Fulcrum Therapeutics Announces REACH, a Phase 3 Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy
CAMBRIDGE, Mass., March 03, 2022. Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced its plans to initiate REACH, a Phase 3... (Source: Drugs.com - Clinical Trials)
Source: Drugs.com - Clinical Trials - March 3, 2022 Category: Pharmaceuticals Source Type: clinical trials
Data Collection of Patients With Rare Bone Diseases
Condition: Rare Disease With Predominantly Skeletal Involvement Intervention: Sponsor: Istituto Ortopedico Rizzoli Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 21, 2022 Category: Research Source Type: clinical trials
Clinical Trial Data Set Re-use With Statistical Methodologies Tailored for Clinical Trials in Rare Diseases
Conditions: Tuberous Sclerosis; Epilepsy Intervention: Sponsors: Imagine Institute; RWTH Aachen University; Ruhr University of Bochum; Medical University of Warsaw Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 20, 2022 Category: Research Source Type: clinical trials
